title: Placental weight and mortality in premenopausal breast cancer by tumor characteristics.
abstract: Placental weight may be regarded as an indirect marker of hormone exposures during pregnancy. There is epidemiological evidence that breast cancer mortality in premenopausal women increases with placental weight in the most recent pregnancy. We investigated if this association differs by tumor characteristics, including expression of estrogen and progesterone receptors. In a Swedish population-based cohort, we followed 1,067 women with premenopausal breast cancer diagnosed from 1992 to 2006. Using Cox regression models, we estimated hazard ratios for the association between placental weight and risk of premenopausal breast cancer mortality. In stratified analyses, we estimated mortality risks in subjects with different tumor stages, estrogen receptor (ER) or progesterone receptor (PR) status. Compared with women with placental weight less than 600 g, women with a placental weight between 600 and 699 g were at a 50 % increased risk of mortality, however, not significant change in risk was observed for women with placental weight ≥ 700 g. Mortality risks associated with higher placental weight were more pronounced among ER(-) and PR(-) breast cancer tumors, where both a placental weight 600-699 g and ≥ 700 g were associated with a more than doubled mortality risks compared with tumors among women with placental weight less than 600 g. Moreover, stratified analyses for joint receptor status revealed that a consistent increased mortality risk by placental weight was only apparent in women with ER(-)/PR(-) breast cancer. The increased mortality risk in premenopausal breast cancer associated with higher placental weight was most pronounced among ER(-) and PR(-) tumors.
authors.affiliation: Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden. Mohammadhossein.Hajiebrahimi@ki.se
authors.forename: Mohammad Hossein
authors.initials: MH
authors.lastname: Hajiebrahimi
authors.forename: Shahram
authors.initials: S
authors.lastname: Bahmanyar
authors.forename: Mats
authors.initials: M
authors.lastname: Lambe
authors.forename: Jan
authors.initials: J
authors.lastname: Adolfsson
authors.forename: Tommy
authors.initials: T
authors.lastname: Fornander
authors.forename: Fredrik
authors.initials: F
authors.lastname: Wärnberg
authors.forename: Sven
authors.initials: S
authors.lastname: Cnattingius
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000378:metabolism / Q000401:mortality*; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism / Q000401:mortality*; D018275:Carcinoma, Lobular / Q000378:metabolism / Q000401:mortality*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009929:Organ Size; D010920:Placenta / Q000473:pathology*; D011247:Pregnancy; D017697:Premenopause; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012306:Risk; D013548:Sweden / Q000453:epidemiology
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone